A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
Brief description of study
The main goal of this phase Ib/2 study is to evaluate safety, preliminary antitumor activity of the investigational drug, Avelumab, a PD-L1 monoclonal antibody, in combinations with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors.
Clinical Study Identifier: s16-02110
ClinicalTrials.gov Identifier: NCTs16-02110
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
